Tesamorelin

A synthetic GHRH analog particularly well studied for visceral abdominal fat and body composition research.

Typical bottle: 10–20 mg

Research note: Tesamorelin is one of the few GH-axis peptides with a genuine FDA-approved indication (for HIV-associated lipodystrophy) supporting its GHRH mechanism, though the broader research-community dosing protocols below go beyond that approved use.

What It Is

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate the body’s own production of growth hormone. It is particularly well known for research involving visceral abdominal fat and body composition.

By activating GHRH receptors in the pituitary, Tesamorelin encourages natural GH release, which subsequently influences IGF-1, fat metabolism, tissue repair, and body composition — working upstream rather than supplying growth hormone directly.

Who May Benefit

Visceral abdominal fat research
Body composition
Metabolic health
Growth hormone signaling
Fat metabolism
Lean-tissue preservation
Recovery and tissue repair
Changes in body composition associated with aging

What to Expect

Tesamorelin is researched as a body-composition and growth-hormone-axis compound, with particular interest around visceral abdominal fat specifically — not just total body weight.

Changes in body composition generally occur progressively over months rather than immediately. Individual response varies, and water retention or other adaptation effects may occur early in a protocol.

What to Pair It With

CJC-1295 + Ipamorelin

Complementary growth-hormone signaling pathways for recovery, sleep, and body composition research.

IGF-1 LR3

Focuses more directly on IGF-1 signaling, muscle growth, recovery, and tissue development.

Ipamorelin

Adds a ghrelin-mimetic GHRP pathway alongside Tesamorelin’s GHRH mechanism.

Reconstitution

10 mg Vial

1 mL Bac. Water

20 mg Vial

2 mL Bac. Water

Final Concentration

10 mg/mL (both)

5 units = 500 mcg10 units = 1 mg

Suggested Research Dosing Strategy

Provided Research Reference

500 mcg–1 mg

Daily · subcutaneous · the source protocol describes 4–5 months ON, 4 weeks OFF, then reassess.

Estimated requirement: approximately 20 mg per month. A 20 mg vial provides roughly 4 weeks at a 5 days on / 2 days off schedule using this dosing approach. If water retention occurs, the source protocol suggests reducing the dose and re-titrating gradually.

Administration Notes

Subcutaneous administration. The source protocol recommends a fasted state depending on the research objective.

Maintain appropriate sterile handling and storage practices, and monitor individual response and tolerability throughout the research period.

Research Considerations

Tesamorelin’s signaling chain runs Tesamorelin → GHRH receptor → growth hormone → IGF-1, involved in fat metabolism, body composition, protein synthesis, tissue repair, and cellular growth.

Its most notable research area is visceral adipose tissue specifically — the metabolically active fat around internal organs — which is why body-composition and visceral-fat measurements are often more informative than scale weight alone when evaluating this compound.

Have a specific question about Tesamorelin? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.

All Peptides by Goal